ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.Annals of clinical and translational neurology · 2026Article
- Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey.BMC neurology · 2025Article
- Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non-Optic Neuritis Onset.European journal of neurology · 2025Article
- Longitudinal Changes in Neuroaxonal and Inflammatory CSF Biomarkers in Multiple Sclerosis Patients Undergoing Interferon Beta Therapy.Biomedicines · 2025Article
- The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.eNeurologicalSci · 2025Review
- Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.Journal of neurology · 2024Article
- High heterogeneity of cross-reactive immunoglobulins in multiple sclerosis presumes combining of B-cell epitopes for diagnostics: a case-control study.Frontiers in immunology · 2024Article
- Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis.Nature communications · 2023Article
- High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2023Article
- No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.International journal of molecular sciences · 2022Review
- Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurofilament light (NFL) has been increasingly recognized for prognostic and therapeutic decisions.
objectiveTo validate the utility of cerebrospinal fluid NFL (cNFL) as a biomarker in clinical practice of relapsing-remitting multiple sclerosis (RRMS).
methodsRRMS patients (
resultsRRMS with relapse had 4.4 times higher median cNFL concentration (1134 [interquartile range (IQR) 499-2744] ng/L) than those without relapse (264 [125-537] ng/L,
conclusionscNFL is a robust and reliable biomarker of disease activity, treatment response, and prediction of disability and conversion from RRMS to SPMS. Our data suggest that cNFL should be included in the assessment of patients at MS-onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.